Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients. Academic Article uri icon

Overview

MeSH

  • Adult
  • Chromosome Aberrations
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Recurrence
  • Remission Induction
  • Survival Analysis
  • Treatment Outcome
  • Young Adult

MeSH Major

  • Leukemia, Myeloid, Acute

abstract

  • We examined 1229 younger patients with acute myeloid leukemia who achieved CR1 on Eastern Cooperative Oncology Group trials. We defined late relapse as occurring after ≥ 3 years of CR1. With median follow-up of 11.3 years, there were 14 late relapses (1.1% of CR1 patients; 3.3% of 3-year CR1 patients). Eight achieved second CR and median overall survival after late relapse was 3.2 years. Most patients tested (9/11) had a normal karyotype at diagnosis; none had new cytogenetic abnormalities at relapse. Late relapse is rare and nearly all 3-year CR1 patients are cured. If late relapse occurs, outcomes are relatively favorable. Copyright © 2014 Elsevier Ltd. All rights reserved.

publication date

  • August 2014

has subject area

  • Adult
  • Chromosome Aberrations
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Leukemia, Myeloid, Acute
  • Male
  • Middle Aged
  • Prognosis
  • Recurrence
  • Remission Induction
  • Survival Analysis
  • Treatment Outcome
  • Young Adult

Research

keywords

  • Journal Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4326112

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2014.05.018

PubMed ID

  • 24986381

Additional Document Info

start page

  • 901

end page

  • 906

volume

  • 38

number

  • 8